Portage Biotech Inc. Sells 22,996 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) major shareholder Portage Biotech Inc. sold 22,996 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $30.03, for a total value of $690,569.88. Following the completion of the sale, the insider now owns 6,278,504 shares in the company, valued at approximately $188,543,475.12. The transaction was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Portage Biotech Inc. also recently made the following trade(s):

  • On Friday, January 19th, Portage Biotech Inc. sold 35,119 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.03, for a total value of $1,054,623.57.
  • On Tuesday, January 23rd, Portage Biotech Inc. sold 59,396 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $135,520.00, for a total value of $8,049,345,920.00.
  • On Tuesday, January 9th, Portage Biotech Inc. sold 84,881 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $30.06, for a total value of $2,551,522.86.
  • On Wednesday, January 3rd, Portage Biotech Inc. sold 35,650 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $28.61, for a total value of $1,019,946.50.

Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) traded down $0.64 during midday trading on Friday, reaching $32.06. The company had a trading volume of 267,635 shares, compared to its average volume of 457,035. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $17.00 and a 1 year high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($1.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. equities analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of BHVN. Legal & General Group Plc acquired a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth $119,000. Nationwide Fund Advisors acquired a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth $214,000. American International Group Inc. acquired a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth $251,000. State of Wisconsin Investment Board acquired a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth $262,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth $302,000. 47.76% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have recently issued reports on the company. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. BidaskClub lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 target price on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Monday, December 11th. Finally, Canaccord Genuity assumed coverage on Biohaven Pharmaceutical in a research note on Friday, December 15th. They issued a “buy” rating and a $30.00 price objective for the company. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Biohaven Pharmaceutical currently has an average rating of “Buy” and an average price target of $36.14.

TRADEMARK VIOLATION WARNING: “Portage Biotech Inc. Sells 22,996 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/02/portage-biotech-inc-sells-22996-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply